Senti Biosciences Inc
For the period ended Mar 31, 2025. Filed May 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 6, 2025
SNTI$0.14-11.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating expenses: | ||
| Research and development (including related party costs of $4,070 and $3,632 for the three months ended March 31, 2025 and March 31, 2024, respectively) | 9,281 | 8,779 |
| General and administrative | 7,116 | 7,522 |
| Total operating expenses | 16,397 | 16,301 |
| Loss from operations | (16,397) | (16,301) |
| Other income: | ||
| Interest income | 394 | 331 |
| GeneFab sublease income - related party | 1,713 | 1,461 |
| Other income | 178 | — |
| Change in fair value of GeneFab Option - related party | — | 2,314 |
| Change in fair value of GeneFab Economic Share - related party | — | 55 |
| Change in fair value of GeneFab Note Receivable - related party | — | 29 |
| Total other income | 2,285 | 4,190 |
| Net loss | $(14,112) | $(12,111) |
| Comprehensive loss | $(14,112) | $(12,111) |
| Basic and diluted net loss | $(14,112) | $(12,111) |
| Basic and diluted net loss per share | $(1.41) | $(2.65) |
| Basic and diluted weighted-average number of shares used in computing net loss per share | 10,012,908 | 4,570,744 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.